Pfizer 和 Eli Lilly 预测增长,尽管在大规模销售后面临挑战,但回报仍大有希望。 Pfizer and Eli Lilly forecast growth, offering promising returns despite post-pandemic sales challenges.

Pfizer预测会增长, 特别是在肿瘤学方面, 提供6.3%的股息收益。 Despite a sales dip post-pandemic, Pfizer is forecast to grow, particularly in oncology, offering a 6.3% dividend yield. Pfizer的交易低于预期收入,可在三到四年内提供20%的年化回报率。 Trading below expected earnings, Pfizer could offer a 20% annualized return over three to four years. 同时,以Eli Lilly为主的Mounjaro和Zepbound等糖尿病和肥胖症治疗也似乎是一项强劲的投资,收入大幅增长,新设施投资45亿美元。 Meanwhile, Eli Lilly, with its focus on diabetes and obesity treatments like Mounjaro and Zepbound, also appears as a strong investment, showing significant revenue growth and a $4.5 billion investment in new facilities.